Return to search

Pervasis Adds $9.75 Million

Pervasis Therapeutics Inc., a Cambridge, Mass.-based developer of regenerative cell-based therapies and devices, has raised $9.75 million in Series B-1 funding. Return backers include Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.

 

PRESS RELEASE

Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and devices, today announced that it has secured $9.75 million in additional financing through Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.

The new investment will support further development of Pervasis' innovative Vascugel